Archive for the ‘BioTechnology – Venture Creation’ Category

Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery


Reporter: Aviva Lev-Ari, PhD, RN


GlaxoSmithKline, UC’s Doudna Establish $67M Genomics, CRISPR Research Lab

Jun 13, 2019   |  staff reporter

Save for later


NEW YORK (GenomeWeb) – Drug company GlaxoSmithKline announced today that it will establish a laboratory for CRISPR technologies as part of a five-year collaboration with University of California researchers.

The new Laboratory for Genomics Research (LGR) will investigate disease-causing gene mutations and develop new technologies using CRISPR to accelerate the discovery of new drugs, with a focus on immunology, oncology, and neuroscience. The LGR will receive up to $67 million in funding over the five-year collaboration period, including facilities for 24 full-time university employees funded by GSK, plus up to 14 full-time GSK employees, the company said. GSK’s artificial intelligence and machine learning group will also aid in building any necessary bioinformatics pipelines. The laboratory will be based near the University of California, San Francisco’s Mission Bay campus.

The LGR aims to automate existing CRISPR approaches so that this work can be done at scale. Ultimately, the lab’s goal is to deepen researchers’ understanding of genetics and discover new drug targets. They’re also aiming to create next-generation technologies for the pharmaceutical industry, GSK added.

The LGR will also serve as a resource for investigators at both UCSF and the University of California, Berkeley who can access and use its technology to answer their own research questions and to develop new tools.

The LGR was developed by Berkeley professor and CRISPR expert Jennifer Doudna, UCSF Professor Jonathan Weissman, and GSK CSO and President of R&D Hal Barron.

“Over the last seven years, CRISPR has transformed academic research, but until the LGR, we haven’t had a focused effort to catalyze the kind of research we know will lead to new innovation using this CRISPR tool,” Doudna said in a statement. “LGR is about building that space where creative science is partnered with the development of robust technology that will help develop tomorrow’s drugs. I think we’re going to be able to do science that none of us can even imagine today.”

The collaboration will be governed by a Joint Steering Committee with equitable UC and GSK representation, with additional joint sub-committees covering patents, scientific, and project management, GSK noted. Doudna and Weissman will sit on the committee along with GSK’s new head of functional genomics, Chris Miller.

“One of our key goals is to advance the field overall and make these tools as broadly available as possible,” Weissman added in the statement. “The LGR screening center will enable labs at UCSF and Berkeley, and having access to it will give our scientists opportunities to advance their research in ways that would be very hard for them to do in their own labs.”





Other related articles published in this Open Access Online Scientific Journal include the following 156 articles:




Read Full Post »

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Science and technology bring tremendous value to society in years of life and quality of life, yet the public often perceives science as difficult, irrelevant or even threatening. Moreover, the inspirational and moving stories of scientists and innovators working around the world are often hidden or misrepresented in popular culture. Whose responsibility is it to communicate science and engage the public in supporting the scientific enterprise? Can everyone be a Champion of Science and what are the solutions to enlist and engage more champions of science across generations and geographies? How do we work together to enhance transparency, accessibility and relevance of science for everyone, everywhere? Can science become more inclusive and engage hearts and not only minds?

Join this exciting session as Johnson & Johnson announces the winners of the Champions of Science – BioGENEius Storytelling Challenge, and brings together other key stakeholders in a discussion about the importance of engaging the public to fall in love in science all over again.

Sponsored by: Johnson & Johnson Innovation

Seema: We need to solve the problem of the lack of trust in scientists.  Some of JNJ winners of their acheivement program went on to become Nobel Laureates.   Arthur Horwich and Hans Ullrich won the Jannsen Award for discovering compounds that could refold proteins, including protein chaperones.  Many diseases occur because of protein misfolding like neuro-degenerative diseases.
Seema:  Great science going on in Africa.  JNJ wanted to showcase the great science in Africa. they awarded four individuals with storytelling award (Emily).
Dr. Horwich: got interested in science early on.  Worked on N terminal mitochondrial signal peptides.  also then got interested in how proteins fold and unfold and refold since the 1950s.  He had changed the thinking of how proteins are processed within cells and over many years he had worked on this.
Emily Wang:  Parents and schoolteachers prodded her curiosity in biology. The impact of day to day work of scientists is arduous but the little things can lead to advances that may help people.  If passionate and have a great mentor then can get a foot in the door.  Worked at Stanford in the lab.
Dr. Mukherjee: He likes to cure diseases, physican first, scientist second, writer third but he doesn’t separate this.  In older times scientists wrote to think and true today. How we visualize the word, or use our hands, is similar.  He takes the word translational research very seriously.  Can you say in one sentence how this will help patients in three years?
There are multitude ways of love for science.
Dr. Pinela: loved asking big question and loved storytelling but asking bigger questions. Moved from Columbia and moved to US; loved the freedom and government funding situation at that time.  Need the training and mentorship so mentors are a very big aspect in innovation as it led her to entrepreneurship.  We need to use technology to disrupt and innovate.
Nsikin:  A lot of mentors nurture curiosity.  People like to see them in that story of curiosity.  That is how is bases the PBS science videos: did  a study on engagement and people wants a morality, and a science identity (an inner nerd in all of us i.e. spark the interest).  The feedback if they focus on this has been positive.

Please follow LIVE on TWITTER using the following @ handles and # hashtags:





# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

Each country have their own needs and most important drug cost structure. Must involve patients and providers.
BCI survey: countries output different, who improved who didnt
Is industry having collaboration with government? hardly ten percent by survey and worse vice versa
Transparancy and holistic view important for collaboration
Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments
Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance
Pitts: we need trust; staff that country offices with people who know that country. Price not defining value
Columbia:  need to attract investors

Please follow LIVE on TWITTER using the following @ handles and # hashtags:





# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »

Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2


Results from Clarivate
In 2018 most of deals were in CART area but now we are seeing more series A rounds that are on novel mechanisms as well as rare diseases.  US is still highest in venture capital series A but next is China. 10 of top ex US VC are from China, a whole lot of money.
Preclinical is very strong for US VC but China VC is focused on clinical.  First time this year we see US series A break above 100.  But ex US the series A is going down.  Although preclinical deals in US is coming back not like as good as in 2006.  But alot of > 1 billion $ deals.  Most of money into mAbs and protein therapy;  antisense is big and cell therapy is big too; small molecule not as much
ClearView Healthcare
Which innovation classes attracted VC in 2018?
  • Oncology drives a disproportionate focus could be driven by pharma focus on oncology; however there is some focus on neuro and infectious disease
  • therapeutic classes: shift to differentiated technology…. companies want technologic platforms not just drugs.  Nucleic Acid tech and antibody tech is high need platforms.  Startups can win by developing a strong platform not just a drug
There are pros and cons of developing a platform company versus a focused company.  Many VCs have a portfolio and want something to fit in so look for a focused company and may not want a platform company.  Pfizer feels that when alot of money is available (like now) platform investing is fine but when money becomes limited they will focus on those are what will be needed to fill therapy gaps.  They believe buy the therapy and only rent the platform.
Merck does feel the way Pfizer does but they have separate ventures so they can look and license platforms.  they are active in looking at companies with new modalities but they are focused on the money so they feel best kept in hands of biotech not pharma.
At Celgene they were solely focused on approvals not platforms.  Alot of money is required to get these platforms to market.  Concentration for platform companies should be the VCs not partnering or getting bought out by pharma.  it seems from panel speakers from pharma that they are waiting for science to prove itself and waiting for favorable monetary environments (easy money).  However it seems they (big pharma) are indicating that money is drying up or at least expect it too.
At Axial and with VCs they feel it is important to paint a picture or a vision at the early stage.
At Ontogeny, they focus on evaluating assets especially and most important, ThE MANAGEMENT TEAM.  There are not that many great talented drug development management teams he feels out there even though great science out there.

Read Full Post »

Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Please follow LIVE on TWITTER using the following @ handles and # hashtags:





# Hashtags

#BIO2019 (official meeting hashtag)

Please check daily on this OPEN ACCESS JOURNAL for updates on one of the most important BIO Conferences of the year for meeting notes, posts, as well as occasional PODCASTS.


The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.  The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.


Keynote Speakers INCLUDE:

Fireside Chat with Margaret (Peggy) Hamburg, MD, Foreign Secretary, National Academy of Medicine; Chairman of the Board, American Association for the Advancement of Science

Tuesday Keynote: Siddhartha Mukherjee (Author of the bestsellers Emperor of All Maladies: A Biography of Cancer and  The Gene: An Intimate History)

Fireside Chat with Jeffrey Solomon, Chief Executive Officer, COWEN

Fireside Chat with Christi Shaw, Senior Vice President and President, Lilly BIO-Medicines, Eli Lilly and Company

Wednesday Keynote: Jamie Dimon (Chairman JP Morgan Chase)

Fireside Chat with Kenneth C. Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

Fireside Chat: Understanding the Voices of Patients: Unique Perspectives on Healthcare

Fireside Chat: FDA Town Hall



Super Session: What’s Next: The Landscape of Innovation in 2019 and Beyond

Super Session: Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Digital Health in Practice: A Conversation with Ameet Nathawani, Chief Digital Officer, Chief Medical Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Realizing the Promise of Gene Therapies for Patients Around the World

Super Session: Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Super Session: The Art & Science of R&D Innovation and Productivity

Super Session: Dealmaker’s Intentions: 2019 Market Outlook

Super Session: The State of the Vaccine Industry: Stimulating Sustainable Growth


See here for full AGENDA

Link for Registration:

The BIO International Convention is literally where hundreds of deals and partnerships have been made over the years.


BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

In addition, we produce BIOtechNOW, an online blog chronicling ‘innovations transforming our world’ and the BIO Newsletter, the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.


Membership with the Biotechnology Innovation Organization (BIO)

BIO has a diverse membership that is comprised of  companies from all facets of biotechnology. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies – 90 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. Learn more about how you can save with BIO Membership.

BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • 66% R&D-Intensive Companies *Of those: 89% have annual revenues under $25 million,  4% have annual revenues between $25 million and $1 billion, 7% have annual revenues over $1 billion.
  • 16% Nonprofit/Academic
  • 11% Service Providers
  • 7% State/International Affiliate Organizations

Other posts on LIVE CONFERENCE COVERAGE using Social Media on this OPEN ACCESS JOURNAL and OTHER Conferences Covered please see the following link at


Notable Conferences Covered THIS YEAR INCLUDE: (see full list from 2013 at this link)

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT


  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge


  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON


  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing


  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York


  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge


  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School


  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA


Read Full Post »

CytoReason is re-defining the Context of the Immune System for Drug Discovery

Reporter: Aviva Lev-Ari, PhD, RN


CytoReason is re-defining the context of the immune system at a cellular level in order to better understand disease and support more effective drug discovery and development.

Our leading-edge machine-learning driven approach identifies “cause and effect” of the gene/cell/cytokine relationships that lie at the heart of treating disease.

Faster and more accurately than ever before.

CytoReason’s mission is to simulate the cells that can stimulate discovery of:​

  • New targets for treating disease
  • New insights to mechanism of actions (both of disease and drugs)
  • Differences in responses to both disease and treatment
  • Which diseases a drug can impact

We have developed a unique machine-learning driven approach to “seeing” the cells that can make the difference in patients seeing a better life.

The insights our approach generates, enable pharmaceutical and biotech companies to make the right decisions, at the right time, in the drug discovery and development programs that bring better therapies.

Based on cutting edge technologies, trained on data that would normally be impossible to access, and steered by leading biological and data science researchers, our approach is underpinned by three core principles:​


Press Release

Case Studies

Click one of the buttons below to view a short case study presention:

Collaboration & Results

Working with leading global pharma and biotech companies and key research institutions, our results help guide R&D decision making.


Our platform is tried and tested, producing real results with validation

•    Discovered: New cellular players in melanoma microenvironment

•    Discovered: New IL4 mechanism of action in atopic dermatitis

•    Discovered: Novel pre-treatment biomarkers in IBD anti-TNFα therapy

•    Discovered: 355 previously unreported cell/cytokine interactions (view infographic)


Science is the backbone of our methodologies and applications, and must stand the test of scientific scrutiny.  To date we have 16 research papers published in top quality peer-reviewed scientific journals, including four in 2018 alone – 3 of which were published in journals from the Nature group



Shen-Orr told Forbes in an article published late last month that CytoReason’s tech is able to calculate immune age in one of two ways: “Via cell-subset composition nearest neighbor approach or based on a gene expression signature where the genes are predictive of the cell-subsets composition, and they test for their enrichment in the gene expression pattern of the sample. The immune profiles of individuals are used to predict immune changes based on a machine learning methodology deployed on data on a range of cell-subsets. ”

“The immune age is a biological clock that will help to identify, the decline and progress in immunity that occurs in old age, to determine preventive measures and develop new treatment modalities to minimize chronic disease and death,” he added.

CytoReason’s tech has so far yielded two pending patents, 10 commercial and scientific collaborations, and 16 peer-reviewed publications.

Harel says it was a combination of forces that made CytoReason’s immune-focused methodology work: Big Data, machine learning, and biology. He describes it as “the intersection of computer science and biology.”

SEE ALSO: The Future Of Medicine: Israeli Scientists Unveil New Tech To 3D-Print Personalized Drugs


Professor Magdassi tells NoCamels that with 3D printing of hydrogels, molecules that are soluble in water, scientists can improve the performance of the drug through its delivery. For example, “the hydrogel once ingested can be designed to swell, releasing two, or three, or four drugs at a time [or with a delay] or it can be designed not to swell, depending on what we are trying to achieve.”

“The drug can be tailored to the patient because of the unique shape or structure of the hydrogel and/or its release behavior,” Professor Magdassi explains.

Currently, there is one 3D-printed drug on the market. In 2015, the US Food and Drug Administration (FDA) approved Spritam, a 3D-printed powdered drug in pill form for the treatment of epileptic seizures, designed to dissolve faster than other pills.



Quantifying The Age Of Our Immune System Could Bring Us Some Steps Closer To Precision Medicine

Last January, CytoReason announced an agreement with Pfizer, in which the latter will leverage the former’s technology to create cell-based models of the immune system. According to the agreement, CytoReason will receive an undisclosed amount in the low double-digit millions of U.S. dollars from Pfizer in access fees, research support and success-based payments. Prof. Shen-Orr concluded, “The immune age is a biological clock that will help to identify, the decline and progress in immunity that occurs in old age, to determine preventive measures and develop new treatment modalities to minimize chronic disease and death.”

Read Full Post »

MIXiii-BIOMED 2019 – The 18th National Life Science & Technology Week, May 14-16, 2019, David InterContinental, Tel Aviv, Israel



Daily Program

NB: Please check program on site in case of last minute changes.

Time slots in blue text indicate Company Presentations. Click on company name to view abstract.

14 May 2019

09:30  –  11:20
Hall A

Opening Session

09:30-10:00 Welcome by Conference Chairpersons:
Ruti Alon, Founder and CEO, Medstrada
Ora Dar, PhD, Israel Innovation Authority
Nissim Darvish, MD, PhD, Senior Managing Director, Orbimed Advisors

10:00-10:40 Robert C. King, PhD, Partner at Goldman Sachs International and Global Vice Chairman, Investment Banking Division: “Current Developments in Healthcare Capital Markets and M&A”

10:40-11:20 Barry Greene, President, Alnylam Pharmaceuticals: “Nobel Prize-Winning Science to First Approved RNAi therapeutic”

11:20  –  11:50

Coffee Break

11:50  –  17:40
Hall A

Gene Editing and Gene Therapy: The Next Frontier in Human Health

Co-chairs: Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; Stephen Squinto, PhD, Interim CEO, Passage Bio

11:50-11:55 Opening by Co-chairs

11:55-12:20 Adi Barzel, PhD, Senior Lecturer, Department of Biochemistry at Tel Aviv University; Co-Founder of LogicBio Therapeutics, Inc.; President of the Israeli Society of Gene and Cell Therapy: “Principles of Gene Editing; CRISPR in B Cells Fighting AIDS”

12:20-12:40 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Novel Approaches for Antibody-targeted Intracellular Delivery of Large Nucleic Acids incl. CRISPR Mediated Gene Editing Modules”

12:40-13:00 Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco: “CRISPRa Therapeutics for Haploinsufficient Disease”

13:00-13:20 Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences

13:20-13:35 Kyle Chiang, PhD, VP Product Strategy, LogicBio Therapeutics“In Vivo Genome-editing for Rare Pediatric Diseases”

13:35-13:50 David Baram, PhD, Chief Executive Officer, Emendo Bio Inc“Emendo Biotherapeutics – High Precision Gene Editing with Next Generation CRISPR Nucleases”

13:50-15:20 Lunch Break

15:20-15:45 Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College: “Gene Therapy for CNS Disorders”

15:45-16:05 Stephen Squinto, PhD, Interim CEO, Passage Bio: “Passage Bio: Developing Transformative Genetic Medicines for Rare Monogenic CNS Diseases”

16:05-16:25 Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx; “Using Gene Therapy for the Treatment of Rare Genetic Liver Disease”

16:25-16:40 Trevor Martin, PhD, CEO and Co-Founder, Mammoth Biosciences: “The Next Generation of CRISPR Tools”

16:40-16:55 Dalia El-Ani, PhD, Chief Executive Officer, CRISPR Stem & Therapeutics“CRISPR: A Novel Gene Therapy to Protect the Heart from Acute Ischemic Damage”

16:55-17:40 “Panel Discussion
Ronald G. Crystal, MD, Founder, LEXEO Therapeutics and Chair, Department of Genetic Medicine, Weill Cornell Medical College
Rachel Haurwitz, PhD, Co-founder, President and CEO, Caribou Biosciences
Prof. Nadav Ahituv, PhD, Department of Bioengineering and Therapeutic Science, University of California San Francisco
Yael Weiss, MD, PhD, Vice President Business Development, Ultragenyx
Stephen Squinto, PhD, Interim CEO, Passage Bio

11:50  –  17:25
Hall B

Transforming Medicine: Artificial Intelligence and Digital Health

Co-chairs: Anat Naschitz, Managing Director, OrbiMed Advisors; Allen Kamer, Managing Partner, OurCrowd Qure

11:50-11:55 Opening by Co-chairs

11:55-12:20 Don Mathis, General Manager, Growth, Comcast NBCUniversal: “Changing Healthcare at Scale: How AI is Enabling Transformation”

12:20-12:45 Elliot Menschik, MD, PhD, Global Head Healthcare and Lifescience Startups, Amazon: “Democratizing AI/ML Capabilities and Accelerating their Impact on Healthcare”

12:45-13:00 Leif E. Pedersen, CEO, Dassault Systemes BIOVIA: “Real Life Examples of BioPharma Leveraging AI and Machine Learning”

13:00-13:15 Doron Behar, MD, PhD, CEO, Igentify“An End-to-end & Scalable Digital Platform Designed for Web-assisted Genetic Counselling”

13:15-13:30 Yaron Gurovich, CTO, FDNA“Hype vs. Hope: Using AI to Detect Disease”

13:30-13:45 Itay Bengad, CEO, MDGO: “Your Car Knows your Injuries”

13:50-15:20 Lunch Break

15:20-15:40 Avinatan Hassidim, Head of TLV Research, Google: “How Google uses Machine Learning for Medical Research”

15:40-15:55 Ziv Ofek, Founder and CEO, MDClone: “Democratizing Healthcare Data – today and Tomorrow”

15:55-16:10 Hadas Bitran, Head of Healthcare Israel, Microsoft: “Microsoft – Healthcare Innovation”

16:10-16:25 Tamara Mansfeld, Global Innovation Lead, Pfizer: “AI in Drug Discovery”

16:25-16:40 David Harel, Founder and CEO, CytoReason“Machine Learning for Drug Discovery and Development”

16:40-16:55 Avi Veidman, Founder and CEO, Nucleai“Harnessing AI for Pathology”

16:55-17:10 Ariel Beery, Founder and CEO, MobileODT“Using Augmented Reality at the Point of Care to Eliminate Cervical Cancer”

17:10-17:25 Micah Pearlman, COO, Biolojic Design“Making the Intractable Tractable: Designing Multi-Functional, Epitope Specific Antibodies using Machine Learning”

11:50  –  17:25
Hall C

Disruptive and Advanced Medical Devices

Co-chairs: Irit Yaniv, MD, General Partner, Accelmed; Ron Ginor, MD, Venture Partner, OrbiMed Advisors, L.L.C

11:50-11:55 Opening by Co-chairs

11:55-12:10 Bruce R. Rosengard, MD, VP, Global External Innovation, Johnson and Johnson Medical Devices: “Market Perspective”

12:10-12:25 Oren GoldshteinVectorius Medical Technologies“Transforming Heart Failure Treatment with the World’s First In-heart Microcomputer”

12:25-12:40 Ofri Vaisman, COO, Bluewind Medical“Bluewind Medical Renova System – Neurostimulation Therapy for Over Active Bladder”

12:40-12:55 Ron Aginsky, President, FUSMobile“Non-Invasive Procedure for Interventional Pain Managment Treatment”

13:00-13:15 Nicholas Pachuda, WW Vice President, Orthopedic Innovation, J&J Medical Devices: “Field Specific – Orthopedics”

13:15-13:30 Yehiel Tal, CEO, Collplant Ltd“rhCollagen – the Ideal Building Block for Regenerative Medicine”

13:30-13:45 Boaz Behar, CEO, Digma Medical“Restoring Glycemic Control in Patients with T2D”

13:50-15:20 Lunch Break

15:20-15:35 John J. Smith, MD, Partner, Hogan Lovells: “Regulatory Perspective”

15:35-15:50 Nitai Hanani, CEO, Paragate Medical“Implantable Peritoneal Ultrafiltration Device for Fluid Overload Treatment”

15:50-16:05 David Israeli, CEO, Magenta Medical“Minimally-Invasive Blood Pumps for the Treatment of Acute Heart Failure”

16:05-16:20 Prof. Joel V. Brill, MD, FACP, Chief Medical Officer, Predictive Health. LLC: “Reimbursement Perspective”

16:20-16:35 Yoram Solberg, MD, PhD, VP Clinical Affairs, Brainsgate“Spheno Palatine Ganglion Stimulation for Treatment of Acute Ischemic Stroke”

16:35-16:50 Nathalie Gilat, Senior Director, Nyxoah“Nyxoah – Sleep Apnea Healthtech Company”

16:50-17:05 Shai Policker, Medex Exlerator, “Incubator Perspective”

17:05-17:20 Eric Tansky, Managing Director, Oppenheimer & Co. Inc.: “Funding Perspective”

17:20-17:25 Closing by Co-chairs

15 May 2019

09:30  –  11:40
Hall A

Plenary Session

09:30-09:50 Amy W. Schulman, Managing Partner, LS Polaris Innovation Fund and Polaris Partners: “Building Early Stage Companies within the Biotech Ecosystem: Challenges and Opportunities”

09:50-10:10 Aharon Aharon, CEO, Israel Innovation Authority: “Bio-convergence – the Future of Israeli Healthtech”

10:10-11:00 Corporate Panel: Innovative Biotech/Large Companies/Capital: What’s the Right Formula to Bring Products to Patients?
Moderator: Francois Maisonrouge, Senior Managing Director, Evercore Partners
Fiona de Hemptinne, Venture Partner, UCB Ventures
Miriam Frieden, PhD, MBA, VP of Search and Evaluation, Novo Nordisk
Laurent Choppe, DVM, Managing Partner, Cukierman & Co. Life Sciences
Zafrira Avnur, PhD, CSO & Partner, VP Quark Venture Inc.
Tina Xu, Vice President of Information Technology and Head of Business Innovation, AstraZeneca China

11:00-11:40 Todd Brinton, MD, Corporate Vice President, Advanced Technology and Chief Scientific Officer, Edwards Lifesciences:“Investing in Innovation”


11:40  –  12:10

Coffee Break

12:10  –  17:25
Hall A

Prevention and Rehabilitation: Should the Underdog Begin Barking?

Chair: Naomi Gefen, Deputy Director General, ALYN Hospital

Opening Session

12:10-12:25 Maurit Beeri, MD, Director General, ALYN Hospital: “From Prevention to Rehabilitation”

12:25-12:45 Yoav Medan, PhD: “The Technology Augmented Homo Sapiens“

Circle of Life: Prevention and Rehab for all ages

12:45-13:05 Sagit Arbel-Alon, MD, Deputy Director, Reuth Medical & Rehabilitation Hospital: “Geriatric Rehabilitation”

13:05-13:20 Rafi Fischer, Director of Media Communications, OrCam Technologies“OrCam Technologies – AI-Driven Artificial Vision”

13:20-13:35 Or Retzkin, CEO & Co-founder; EyeControl“EyeControl: Inspiring Communication”

13:35-13:55 Itamar Offer, MD, MPA, CEO, Sabar Health: “Rehabilitation at Home”

13:55-14:10 Yotam Drechsler, CEO, BrainQ technologies“BCI Based Stimulation Device- BQ (BrainQ technologies)”

14:10-15:40 Lunch Break

15:40-15:55 Maurit Beeri, MD, Director General, ALYN Hospital: “Pediatric Rehabilitation”

15:55-16:10 Yotam Bahat, CEO, SENSERUM“SENSERUM – VR for Clinical Use”

Taking Rehab to Another Level – Enabling Meaningful Participation in the Community and Workplace

16:10-16:25 Daniel Barel, CEO, SoftWheel“SoftWheel – Innovative Technology for Mobility Solutions”

16:25-16:50 Yaron Galitzky, General Manager, Devices & Accessories, Microsoft“Xbox Adaptive Controller”

16:50-17:15 Ziv Shilon, Co-founder, COO, 6Degrees: “Be the Hero of your Own Story”

Closing Session:
17:15-17:25 Naomi Gefen, Deputy Director General, ALYN Hospital: “The Future of Technology in Rehab”

12:10  –  17:25
Hall B

Tango of the Two: Academia and Industry

Co-chairs: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University; Yaron Daniely, PhD, CEO, Yissum

12:10-12:30 Jeroen Tas, Chief Innovation & Strategy Officer, Philips

12:30-12:45 Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem: “Sensor-driven Leap in Drug Development on a Chip” 

12:45-13:00 Arnaldo Mayer, PhD, VP, R&D, Voxellence“Voxellence: AI-powered Radiology”

13:00-13:15 Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University: “Monitoring Sleep Stages at Home”

13:15-13:45 Panel discussion: Lessons Learnt by Researchers
Moderator: Prof. Yael Hanein, PhD, School of Electrical Engineering, Tel Aviv University
Prof. David Mirelman, PhD, Weizmann Institute of Science
Prof. Gal Markel, MD, PhD, Tel Aviv University
Prof. Daniel Offen, PhD, Tel Aviv University
Prof. Yaakov Nahmais, PhD, Director, Grass Center for Bioengineering, The Hebrew University of Jerusalem

13:45-14:00 Eran Stark, MD, PhD, Sackler Faculty of MedicineTel Aviv University: “Penetrating Neural Probes”

14:00-14:15 Giora Davidovits, President and CEO, Savicell“A Revolutionary Liquid Biopsy, Immunometabolism Platform for High Accuracy, Early Stage Diagnosis of Diseases”

14:10-15:40 Lunch Break

15:40-15:55 Prof. Tal Dvir, PhD, Tel Aviv University: “Printed Heart”

15:55-16:10 Tomer Behor, CEO, RenewSenses“RenewSenses – Conveying Vision Through Sound”

16:10-16:25 Chen Levin, CEO, Xact Robotics Ltd“XACT Robotics – XACTly on Target Every Time”

16:25-16:40 Uzi Sofer, Alpha TAU Medical“First Alpha-radiation Cancer Treatment for Solid Tumors”

16:40-16:55 Tamar Ben-Yedidia, PhD, CSO, BiondVax Pharmaceuticals Ltd: “Update of the Pivotal, Clinical Efficacy, Phase 3 trial of BiondVax’s M-001 Universal Influenza Vaccine”

16:55-17:45 Panel Discussion: It Takes a Village: Boosting the Volume and Quality of Academic Entrepreneurship
Moderator: Yaron Daniely, PhD, CEO, Yissum
Aviv Zeevi, PhD, VP, Technology Infrastructure Division, Israel Innovation Authority
Kelly Krajnik, Senior Manager, Devices, Diagnostics, Mayo Clinic Ventures
Regine Shevach, Managing Director at Inter-Lab, an affiliate of Merck KGaA
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon
Shai Policker, CEO, Medex Xelerator LP

12:10  –  17:40
Hall C

New Modalities of Cell Therapies: Revolutionizing the Way We Treat Diseases

Co-chairs: Aya Jakobovits, PhD, Founder, Director, Adicet Bio; Erez Chimovits, Senior Managing Director, OrbiMed Advisors

12:10-12:15 Opening remarks by Co-chairs

12:15-12:40 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Adoptive Cell Therapy 3.0”

12:40-13:05 Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors: “The Cell Therapy Field has already Generated some of the Best Returns in Biotechnology, and the Best is Yet to Come, Based on Enhanced Cell Therapy Technologies”

13:05-13:20 Prof. Angel Porgador, PhD, Ben-Gurion University: “Natural Killer (NK) Cells in Cancer Immunotherapy”

13:20-13:35 Michal J. Besser, PhD, Head of Laboratory, Ella Lemelbaum Institute for Immuno Oncology & Director, Wohl GMP Facility, Sheba Medical Center; Assistant Professor, Dept. of Microbiology and Immunology, School of Medicine, Tel Aviv University: “Clinical Experience with In-house Produced CAR T Cells”

13:35-13:50 Stewart Abbot, PhD, Chief Operating Officer, Adicetbio: “Off-the-shelf, Engineered Gamma Delta T-cell Therapies”

13:50-14:05 Merav Beiman, PhD, CEO, ImmPACT-Bio“Next Generation CAR-T Engineering Solving the ‘On-Target’ ‘Off-Tumor’ Issue towards Broader, Safer and Effective CAR-T Therapies”

14:05-14:10 Aya Jakobovits, PhD, Founder, Director, Adicet Bio: “Session #1 Summary”

14:10-15:40 Lunch Break

15:40-15:55 Yoav Ben Ya’acov, CEO, CTG Pharma: “CTG Pharma- Safe CAR T Therapy for Solid Tumors”

15:55-16:10 Amy W. Schulman, Executive Chair, SQZ Therapeutics“SQZ Biotech: Unleashing the Power of Cells”

16:10-16:25 Julian Adams, PhD, Chief Executive Officer, Gamida Cell“Ex- vivo Expansion of Natural Killer (NK) Cells to Treat B-Cell Lymphoma and Multiple Myeloma”

16:25-16:40 Shmulik Hess, CEO, Enlivex Therapeutics R&D LTD“Enilvex Therapeutics, Immune Rebalancing”

16:40-17:40 Panel Discussion: “The Path for Effective and Accessible Cancer Cell Therapy”
Amy W. Schulman, Executive Chair, SQZ Therapeutics
Aya Jakobovits, PhD, Founder, Director, Adicet Bio
Carl L. Gordon, PhD, Managing Partner, OrbiMed Advisors
Stewart Abbot, PhD, Chief Operating Officer, Adicet
Julian Adams, PhD, Chief Executive Officer, Gamida Cell


16 May 2019

09:30  –  10:50
Hall A

Plenary Session

09:30-10:10 Tom Sudow, Director, Business Development, Cleveland Clinic Innovations; Mark D. Stovsky, MD, MBA, FACS, Senior Director, Emerging Business, Cleveland Clinic Ventures: “The Revolutionary Changes in Healthcare Delivery: From Prevention to Rehabilitation and Everything in Between”

10:10-10:50 Jeroen Tas, Chief Innovation & Strategy Officer, Philips: “Creating the Future of Healthcare Through Digital Innovation”

10:50  –  11:20

Coffee Break

11:20  –  17:30
Hall A

Transformative Cancer Therapies

Chair: Prof. David Sidransky, MD, Johns Hopkins School of Medicine; Co-Founder and General Partner, Israel Biotech Fund

11:20-11:25 Opening by Chair

11:25-11:50 Gary Gordon, MD, PhD, Former Vice President, Global Oncology Development, AbbVie, Inc: “The 20 Year Journey of an Oncology Drug”

11:50-12:05 Prof. Elizabeth Croydon, Senior Clinical Director, Oncology – EU Clinical Development, Merck Sharp & Dohme: “MSD Immune-oncology Innovative Therapies”

12:05-12:20 Ruth Ben Yakar, PhD, Chief Executive Officer, BioSight“Biosight Ltd. is Developing BST-236, a Novel Antimetabolite for First-line Treatment of Hematological Malignancies and Disorders”

12:20-12:35 Julian Adams, PhD, Chief Executive Officer, Gamida Cell“Ex Vivo Expanded Cells to Treat Hematological Malignancies”

12:35-12:50 Baruch Schori, Chief Executive Officer, PTM Biosciences“PTM Biosciences is Promoting Precision Medicine by Transforming Post-Translational Modifications into Novel Therapeutic Targets and Biomarkers for Disease Management”

12:50-13:05 Tehila Ben Moshe, PhD, Chief Executive Officer & Co-Founder, Biond Biologics“Biond Biologics: From Innovative Science to the Clinic; Transforming the Treatment of Cancer”

13:05-13:20 Israel Isaac, Chief Executive Officer, Kitov Pharma“NT-219, a First-in-class Dual Inhibitor of STAT3 and IRS1/2 is Overcoming Drug Resistance”

13:20-14:50 Lunch Break

14:50-15:10 Ulrich Brinkmann, PhD, Scientific Director, Roche Pharma Research & Early Development, Roche Diagnostics GmbH: “Bi-Specific Antibodies and Fusion Proteins in Cancer Therapy”

15:10-15:25 Prof. Dror Harats, CEO, Vascular Biogenics“Turning ‘Cold’ Tumor into ‘Hot’ Tumor – Lessons from  VB-111, a Viral Immuno-oncology Agent and VB-611, a Novel Bi-specific Antibody”

15:25-15:40 Roni Mamluk, PhD, Chief Executive Officer, Ayala Pharmaceuticals“Ayala Pharmaceuticals – Precision Oncology Targeted Therapy”

15:40-15:55 Frank Haluska, MD, PhD, Chief Executive Ofiicer, Anchiano Therapeutics“Gene Therapy for Early Stage Bladder Cancer: The Pivotal Program with Inodiftagene”

15:55-16:10 Mark Schoenberg, MD, Chief Medical Officer, UroGen Pharma“UroGen Pharma: Paradigm Changing Technology for Urologic Oncology”

16:10-16:25 Asher Nathan, CEO, NeoTX Therapeutics Ltd“Selective T Cell Redirection (STR): A Second Generation Immunotherapy”

16:25-16:40 Amnon Peled, PhD, Chief Executive Officer, Biokine Therapeutics“Development of First in Class High Affinity Small Molecule Antagonist of a Novel Cancer Target Critical for Tumor Cell Migration and Survival”

16:40-17:00 Concluding Remarks

11:20  –  17:05
Hall B

Personalized Medicine and Digital Health: Lessons Learned and Challenges Ahead

Co-chairs: Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund; Prof. Varda Shalev, MD, MPA, Managing Director, Kahn-Sagol- Maccab Research and Innovation Institute at Maccabi Health Care Services

11:20-11:40 Fireside Chat – The Future Doctor, Patient and In-between
Prof. Varda Shalev, MD, MPA
, Managing Director, Kahn-Sagol- Maccabi Research and Innovation Institute at Maccabi Health Care Services
Yair Schindel, MD, Co-Founder & Managing Partner, aMoon Fund

11:40-11:55 Oren Oz, CEO, Nuvo Group“Reinventing Pregnancy Monitoring and Management for the 21st Century”

11:55-12:10 Seth Salpeter, CTO, Curesponse“A Next Generation Platform for Definitive Treatment Answers in Personalized Cancer Medicine”

12:10-12:30 Michal Rozen-Zvi, Director, Healthcare Informatics, IBM Research: “Learn from Screening Data and Assessing Breast Cancer Risk”

12:30-12:45 Daniella Gilboa, Chief Scientific Officer and Co-Founder, AIVF“Transforming IVF with the Power of Artificial Intelligence”

12:45-13:05 Uma Makhija, Business Development Lead, Digital Health, Otsuka Pharmaceuticals: “Pharma and Digital Therapeutics Partnerships – Opportunities and Challenges”

13:05-13:20 Lihi Segal, CEO, DayTwo“Personalized Nutrition Recommendations for Normalizing Blood Glucose Levels Based on Microbiome, Medical and Personal Records”

13:20-14:50 Lunch Break

14:50-15:10 Prof. Eitan Friedman, MD, PhD, Director & Founder of The Suzanne Levy-Gertner Oncogenetics Unit, Sheba Medical Center

15:10-15:25 Alex Melamud, CEO, Melcap Systems“First Digital Health Affordable System for the Treatment of Overweight and Obesity for Billions”

15:25-15:40 Vince Gao, PhD, Founder & CEO, Govita Tech“Association of Genetic and Metabolic Data Derived from Metabolic Pathways for Personalized Intervention of Chronic Diseases”

15:40-15:55 Erez Gavish, Co-Founder/CEO, 2breathe Technologies Ltd“Can Digital Therapeutics Lower Sympathetic Overactivity?”

15:55-16:15 Elliot Menschik, MD, PhD, Global Head, Healthcare + Life Science Startups, Amazon Web Services: “Re:Inventing Healthcare – Glimpses of Digitally-enhanced, Data-driven Future”

16:15-16:30 Simona Di-Capua, Sr Dir GXR&D Tech & Process Design KFS, Teva“3D Printing – A Novel Approach to Design and Manufacture Personalized Medicines”

16:30-16:45 Lior Wolff, Head of eHealth and Digital Wing at Clalit Health Services“Clalit Health Services Expanding its Telemedicine Offering with TytoCare’s Physical Exam from Home”

16:45-17:05 Wade Ackerman, Partner, FDA Regulatory group, Co-Lead of Digital Health Initiative, Covington & Burling LLP: “Navigating the Evolving Regulation of Personalized Medicine and Digital Health”

11:20  –  17:20
Hall C

Cannabis’ Therapeutic Promise: Hope or Hype?

Co-chairs: Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem; Ayelet Torem, Adv, Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co

11:20-11:45 Dorman Followwill, Senior Partner, Frost & Sullivan: “Outlook for Cannabis as Therapeutic Agent”

11:45-12:05 Prof. Hinanit Koltai, PhD, Agricultural Research Organization (ARO), Volcani Center: “Medical Cannabis: from Weed to Molecules to Drug Development”

12:05-12:25 Prof. Simon Benita, PhD, Head of Nano Delivery Systems, Hebrew University of Jerusalem: “Improvement of CBD and THC Oral Bioavailability using Nano Delivery Systems”

12:25-12:45 Yossi Tam, The Hebrew University of Jerusalem: “Cannabinoid-Based Therapies: Lessons Learned from the Endocannabinoid System”

12:45-13:10 Prof. Raphael Mechoulam, PhD, Hebrew University of Jerusalem: “Cannabinoids: A Look Back and Ahead”

13:20:-14:50 Lunch Break

14:50-15:10 Medy Wiener, MD, Chief Medical Officer, BOL Pharma: “Drug/Cannabinoid Clinical Development Route – Same but Different”

15:10-15:25 Prof. Oded Shoseyov PhD, Co-founder and CSO, GemmaCert Ltd“Remote Sensing of Cannabis; The First Steptowards Standardization and Closing the Learning Cycle”

15:25-15:40 Tamir Gedo, CEO, BOL Pharma“The Winners and Losers of the Global Cannabis Industry”

15:40-15:55 Ascher Shmulewitz, CEO, Therapix Biosciences Ltd“Therapix Biosciences Developing Cannabinoids of the Future”

15:55-16:10 Perry Davidson, CEO, Syqe Medical Ltd: “Medical Cannabis – The Green Elephants in the Room”

16:10-16:25 Dadi Segal, CEO, Panaxia Pharmaceutical Industries Ltd“Panaxia – Manufacturing of Pharmaceutical Cannabis Products”

16:25-16:40 Taher Nassar, VP, Research, Bionanosim Ltd“Bionanosim Ltd-Innovative Nano-Carriers for Improved Cannabis-BNS”

16:40-17:00 Prof. Itamar Raz, MD, Head, The Israeli National Diabetes Council: “Medical Cannabis treatment of Pain and Glycemic Control”

17:00-17:20 Ayelet Torem, Adv., Partner, Hi-Tech & Venture Capital and Head of Global Markets, Amit, Pollak, Matalon & Co: “Medical Cannabis Regulatory Overview”



Read Full Post »

Older Posts »